Agilent Technologies

About: Agilent Technologies is a company organization based out in Santa Clara, California, United States. It is known for research contribution in the topics: Signal & Mass spectrometry. The organization has 7398 authors who have published 11518 publications receiving 262410 citations. The organization is also known as: Agilent Technologies, Inc..

Apparatus and method for minimizing pain perception

Abstract: An apparatus and method for minimizing a subject's pain perception during an invasive medical procedure, such as blood sampling and the like. The apparatus can include a receiving surface constructed to contact a portion of the subject's skin and a vibratory mechanism associated with the receiving surface such that the vibratory mechanism transmits vibrations through the receiving surface and to the subject's skin. An invasive sharp can be substantially permanently supported and moveably disposed with respect to the receiving surface such that the invasive sharp reciprocates between a first position in which the sharp is spaced from the receiving surface, away from the subject's skin, and a second position in which at least a portion of the sharp protrudes through an opening in the receiving surface.

Transcript copy number estimation using a mouse whole-genome oligonucleotide microarray

Abstract: The ability to quantitatively measure the expression of all genes in a given tissue or cell with a single assay is an exciting promise of gene-expression profiling technology. An in situ-synthesized 60-mer oligonucleotide microarray designed to detect transcripts from all mouse genes was validated, as well as a set of exogenous RNA controls derived from the yeast genome (made freely available without restriction), which allow quantitative estimation of absolute endogenous transcript abundance.

Food for Thought ... on mapping the human toxome.

Abstract: The report by the National Research Council of the US National Academy of Sciences, Toxicity Testing in the 21st Century: A Vision and a Strategy, has prompted a discussion about renewing regulatory toxicology - especially for chemicals - by harnessing in vitro tests, in silico approaches, and testing in lower organisms The key change is basing the assessments on mechanisms and toxicant modes of action Identifying pathways of toxicity (PoT), especially on a larger scale, evidently requires omics technologies When the PoT is known, a test battery allowing higher throughput than the current approach can be constructed Here, we propose an extension of this concept to mapping the entirety of PoT in humans: the human toxome Mapping the human toxome will allow us, for the first time, to conclusively identify substances as nontoxic or to identify nontoxic concentrations of substances (ie, concentrations at which no relevant PoT are triggered) The concept is explained, and opportunities and obstacles are discussed, aiming to promote an initiative which will form the core of a Human Toxicology Project to implement Toxicology for the 21st Century